Investigation of attenuation correction for small-animal single photon emission computed tomography

Towards Clinical Development of Scandium Radioisotope Complexes for Use in Nuclear Medicine: Encouraging Prospects with the Chelator 1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic Acid (DOTA) and Its Analogues

Scandium (Sc) isotopes have recently attracted significant attention in the search for new radionuclides with potential uses in personalized medicine, especially in the treatment of specific cancer patient categories. In particular, Sc-43 and Sc-44, as positron emitters with a satisfactory half-life (3.9 and 4.0 h, respectively), are ideal for cancer diagnosis via Positron Emission Tomography (PET). On the other hand, Sc-47, as an emitter of beta particles and low gamma radiation, may be used as a therapeutic radionuclide, which also allows Single-Photon Emission Computed Tomography (SPECT) imaging. As these scandium isotopes follow the same biological pathway and chemical reactivity, they appear to fit perfectly into the "theranostic pair" concept. A step-by-step description, initiating from the moment of scandium isotope production and leading up to their preclinical and clinical trial applications, is presented. Recent developments related to the nuclear reactions selected and employed to produce the radionuclides Sc-43, Sc-44, and Sc-47, the chemical processing of these isotopes and the main target recovery methods are also included. Furthermore, the radiolabeling of the leading chelator, 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA), and its structural analogues with scandium is also discussed and the advantages and disadvantages of scandium complexation are evaluated. Finally, a review of the preclinical studies and clinical trials involving scandium, as well as future challenges for its clinical uses and applications, are presented.

Dual-energy x-ray approach for object/energy-specific attenuation coefficient correction in single-photon emission computed tomography: effects of contrast agent

Purpose: To investigate the influence of radiographic contrast agent on the accuracy of the photon counts arising from the emission of gamma rays of radionuclides in single-photon emission computed tomography (SPECT), when dual-energy x-ray CT (DXCT) is employed for providing object/energy-specific attenuation coefficient correction in SPECT. Approach: Computer simulation was performed for three transmission CT approaches, namely, the conventional (single kVp, unimodal spectrum) x-ray CT, DXCT (single kVp, bimodal spectrum) with basis material decomposition (BMD), and DXCT with BMD followed by basis material coefficients transformation (BMT), to study the effects of these approaches on the accuracy of the photon counts from the SPECT image of a thorax-like phantom. Results: All three CT approaches revealed that the error in the counts was both photon energy and iodine concentration-dependent. Differences in the trending increase/decrease in the errors with the respective increase in iodine concentration and photon energy were observed among the three CT approaches. Of the three, the BMT/SPECT approach resulted in the smallest error in the concentration of radionuclides measured, especially in the contrast agent-filled region, and the optimal level depended on the iodine concentration and photon energy. Conclusion: With a judicious choice of the basis materials and photon energy, it may be possible to take advantage of the benefits of the BMT method to mitigate the accuracy problem in DXCT for quantitative SPECT imaging.

A Step-by-Step Guide for the Novel Radiometal Production for Medical Applications: Case Studies with 68Ga, 44Sc, 177Lu and 161Tb

The production of novel radionuclides is the first step towards the development of new effective radiopharmaceuticals, and the quality thereof directly affects the preclinical and clinical phases. In this review, novel radiometal production for medical applications is briefly elucidated. The production status of the imaging nuclide 44Sc and the therapeutic β--emitter nuclide 161Tb are compared to their more established counterparts, 68Ga and 177Lu according to their targetry, irradiation process, radiochemistry, and quality control aspects. The detailed discussion of these significant issues will help towards the future introduction of these promising radionuclides into drug manufacture for clinical application under Good Manufacturing Practice (GMP).